sarepta duchenne muscular dystrophy

Order byBest matchMost fresh

Sarepta's Duchenne Therapy Sparked Fears

Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy

Sarepta Therapeutics said Monday evening it will pause all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, acceding to a request made by the Food and Drug Administration afte...

· 1h · on MSN

In a reversal, Sarepta says it will pause shipments of gene therapy linked to deaths

· 7h · on MSN

Sarepta’s Duchenne Therapy Sparked Fears Even Before FDA’s Order

· 7h

Sarepta shares slide again as drugmaker bows to FDA pressure to pause gene therapy

Shares of drugmaker Sarepta Therapeutics continued to fall Tuesday after the company said it would comply with a Food and Drug Administration request to pause shipments of its gene therapy following s...

· 9h

Sarepta Faces Fresh Setback. Why Now’s Not the Time to Buy the Stock.

STAT · 13h

In surprise reversal, Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy

BioSpace10h

Sarepta Concedes to FDA Request, Suspends US Shipments of Elevidys

After initially refusing to suspend Elevidys distribution after two deaths, Sarepta has now given in to the FDA’s request, noting the need to maintain a good working relationship with the regulator.

Sarepta Therapeutics crisis is huge blow to Duchenne families, company

Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular dystrophy over safety issues, even as patients and investors expressed growing concern about the company’s decision-making.

1don MSN

FDA Suspends Muscular Dystrophy Drug After 3 Patient Deaths

The U.S. Food and Drug Administration ( FDA) has placed an immediate clinical hold on Sarepta Therapeutics' investigational gene therapy trials for limb girdle muscular dystrophy following three patient deaths potentially linked to the company's treatments.